

Rena Rowan Breast Case Conference 2023-2024

Rena Rowan Breast Case Conference 2023-2024 - 10/5/2023 October 5, 2023 8:00 AM - 9:00 AM PCAM South, 12th Floor, Conference Room 122 or Virtual Platform Bluejeans

Target Audience

This program has been designed for Internal Medicine - Medical Oncology, Pathology - Clinical, Radiation Oncology, Radiology - Nuclear Radiology, Surgery - Complex General Surgical Oncology

Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Delineate institutional and national pathways/guidelines in the management of breast malignancy.
- 1 Discuss multidisciplinary care and discussion to improve outcomes and quality of life.
- 3 Describe the critical role of radiology and pathology in the multidisciplinary management of breast cancer
- 4 Describe how to Increase awareness clinical trials at the ACC and throughout the nation and to enhance enrollment in clinical trials.

Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physicians: Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)* $^{\text{TM}}$. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is for 1.00 contact hours.

Pharmacists: This activity is not approved for pharmacy contact hours

PAs: Penn Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.

This activity is designated for **1.00** AAPA Category 1 CME credit(s). PAs should only claim credit commensurate with the extent of their participation.

Approved for (PSRM) patient safety/risk management designation

Acknowledgement of Commercial Support*

For more information, please contact Archel Collier, Julie Mcdaniel (215) 662-70966, (267) 970-8367

Archel.Collier@pennmedicine.upenn.edu, mcdjulie@upenn.edu

Check your transcript online at https://upenn.cloud-cme.com

None



Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provide products or services that may be relevant to the content of this continuing education activity. For this purpose, we consider relationships of the person involved to include financial relationships of a spouse or partner.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain relationships that created a conflict of interest relevant to the topic of their presentation. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no relevant financial relationships with any commercial interests related to the content of this educational activity. Any peer reviewer with a potential conflict of interest will recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Amy Clark, MD, MD, MSCE	Other Planning Committee Member	Grant or research support-Eli Lilly Grant or research support-Novartis / Amgen (Relationship has ended) Honoraria-GE Healthcare (Relationship has ended) - 06/15/2023
Emily F Conant, MD	Other Planning Committee Member	Grant or research support-iCAD, Inc. Honoraria-Medality (Relationship has ended) Grant or research support-Hologic, Inc. Advisor-Hologic, Inc. Advisor-iCAD, Inc 08/03/2023
Tracy d'Entremont, MD	Other Planning Committee Member	Nothing to disclose - 12/07/2022
Ari Brooks, MS Ed	Other Planning Committee Member	Nothing to disclose - 02/23/2023
Angela DeMichele, MD, MSCE	Other Planning Committee Member	Grant or research support-Pfizer, Inc. Grant or research support-Novartis (Advanced Health Media) Grant or research support-Genentech Grant or research support-Calithera - 12/20/2022
Julia Tchou, MD, PhD	Other Planning Committee Member	Advisor-Sensei bio (Relationship has ended) Consulting Fee-Becton Dickinson - 08/02/2023
Susan Domchek, MD	Other Planning Committee	Consulting Fee-Astra Zeneca Pharmaceuticals

	I	I
	Member	(Relationship has ended) Consulting Fee- Glaxo Smith Kline (Relationship has ended) - 08/15/2023
Lawrence N Shulman, MD	Other Planning Committee Member	Consulting Fee-Genentech (Relationship has ended) - 06/15/2023
Kevin Fox, MD	Other Planning Committee Member	Nothing to disclose - 02/01/2023
Ira J Bleiweiss, MD	Other Planning Committee Member	Nothing to disclose - 08/30/2023
Neil Taunk, MD, MS	Other Planning Committee Member	Consulting Fee-Boston Scientific Corporation Consulting Fee-Point BioPharma Grant or research support-Varian Medical Systems - 07/30/2023
Dahlia Sataloff, MD	Other Planning Committee Member	Nothing to disclose - 07/25/2023
Gary M Freedman, MD	Other Planning Committee Member	Nothing to disclose - 02/01/2023
lgor Makhlin, MD	Other Planning Committee Member	Consulting Fee-Astra Zeneca Pharmaceuticals (Relationship has ended) Consulting Fee-Bayer (Relationship has ended) Consulting Fee-Gilead Sciences, Inc (Relationship has ended) - 02/15/2023
Tammy M Turner , MSN, RN, OCN	Nurse Planner	Nothing to disclose - 03/09/2023
Alina Mateo, MD, MS, FACS	Other Planning Committee Member	Nothing to disclose - 08/16/2023
Payal D Shah, MD	Other Planning Committee Member	Advisor-Astra Zeneca Pharmaceuticals (Relationship has ended) Advisor-Daiichi Sankyo (Relationship has ended) Advisor-Gilead Sciences, Inc (Relationship has ended) Advisor-Biotheranostics (Relationship has ended) - 08/07/2023
Jami D Rothman, MD, FCBC	Other Planning Committee Member	Nothing to disclose - 06/21/2023
Rebecca Fishman, MD	Other Planning Committee Member	Nothing to disclose - 06/29/2023
Rachel Jankowitz, MD	Co-Director	Membership on Advisory Committees or Review Panels, Board Membership, etc Biotheranostics - 08/15/2023
Angela Bradbury, MD	Other Planning Committee Member	Grant or research support-Astra Zeneca Pharmaceuticals Grant or research support- Merck & Co - 02/15/2023
William R Green, MD	Other Planning Committee Member	Nothing to disclose - 08/01/2023
Hayley Knollman, MD	Co-Director, Faculty, Other Planning Committee Member	Nothing to disclose - 06/01/2023
stephanie kochis , PA	Physician Assistant Planner	Nothing to disclose - 06/27/2023
Oluwadamilola Fayanju, MD, Associate Professor	Other Planning Committee Member	Grant or research support-Gilead Sciences, Inc Consulting Fee-Sanofi Genzyme

		(Relationship has ended) - 06/29/2023
II eisna (, Fimore, IVII)	Other Planning Committee Member	Nothing to disclose - 01/17/2023
ISaveri Bhattacharva DO	Other Planning Committee Member	Nothing to disclose - 05/18/2023
Yvette Bell, RN	Nurse Planner	Nothing to disclose - 02/01/2023

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected